Phil Pang, M.D., Ph.D., is the vice president of clinical at VIR. Previously, he served as the chief medical officer at Riboscience, a biotech startup developing small molecule antivirals. Prior to this role, he was director of clinical research with Gilead Sciences, Inc. where he successfully led the 100+ matrix team responsible for the worldwide approval of the hepatitis C blockbuster treatment, Harvoni (sofosbuvir/ledipasivir), and the subsequent filing of eight subsequent supplemental NDAs/Type II variations expanding the patient population eligible for this treatment.
Dr. Pang is a graduate of Columbia University having received his Ph.D. in biochemistry and molecular biophysics from the College of Arts and Sciences and his medical degree from the College of Physicians and Surgeons. He completed his residency and fellowship training at Stanford University and is board certified in internal medical and infectious diseases.